Literature DB >> 7487408

Meningioangiomatosis. A clinicopathologic study including MIB1 immunoreactivity.

R A Prayson1.   

Abstract

OBJECTIVE: To examine the etiology of and clinicopathologic findings associated with meningioangiomatosis and to evaluate MIB1 immunoreactivity (marker of cell proliferation) in this lesion.
DESIGN: Retrospective surgical pathology series of three patients.
SETTING: Tertiary referral center with a high volume of epilepsy surgery. PATIENTS: Individuals with meningioangiomatosis who underwent surgical resection of the lesion.
RESULTS: Three patients aged 11, 14, and 32 years (two females, one male) comprise the study. All patients presented with a history of intractable seizures (2, 3, and 30 years duration). None of the patients had von Recklinghausen's disease. All three patients underwent gross total resection of the lesion, and postoperative seizure-free intervals range from 7 to 15 months. Histologically, the lesion is characterized by a proliferation of blood vessels and meningothelial cells arranged around vessels in the meninges, cortex, and underlying white matter. Psammoma body formation or dystrophic mineralization and gliosis of the intervening parenchyma was observed in all three cases. Bodian stains failed to demonstrate neurofibrillary tangles within intervening parenchymal neurons. Focal epithelial membrane antigen positivity was observed in two lesions and was absent in one. MIB1 staining was observed in two lesions (MIB1 index = 0.8 and 0.6) within the meningothelial cell nuclei and was absent in one case.
CONCLUSIONS: Meningioangiomatosis is a rare malformative or hamartomatous lesion of the central nervous system characterized by a proliferation of vessels and perivascular cuffs of meningothelial cells. Absent MIB1 immunoreactivity or low MIB1 indices in the lesion support the clinical impression of a slow-growing lesion and further support a malformative or hamartomatous etiology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7487408

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  8 in total

1.  Meningioangiomatosis involving the wall of the middle cerebral artery.

Authors:  Marco Giulioni; Nicola Acciarri; Mino Zucchelli; Gianluca Marucci; Filippo Badaloni; Fabio Calbucci
Journal:  J Neurooncol       Date:  2006-03-23       Impact factor: 4.130

2.  Sporadic meningioangiomatosis: imaging findings with histopathologic correlations in seven patients.

Authors:  Tae Yeon Jeon; Ji Hye Kim; Yeon-Lim Suh; Soomin Ahn; So-Young Yoo; Hong Eo
Journal:  Neuroradiology       Date:  2013-10-24       Impact factor: 2.804

3.  Allelic loss on chromosomes 1p32, 9p21, 13q14, 16q22, 17p, and 22q12 in meningiomas associated with meningioangiomatosis and pure meningioangiomatosis.

Authors:  Na Rae Kim; Seong Jin Cho; Yeon-Lim Suh
Journal:  J Neurooncol       Date:  2009-04-05       Impact factor: 4.130

Review 4.  A report of primary brain fibrosarcoma with literature review.

Authors:  Ning Cai; Leonard B Kahn
Journal:  J Neurooncol       Date:  2004-06       Impact factor: 4.130

5.  Meningioangiomatosis: a case report and literature review emphasizing diverse appearance on different imaging modalities.

Authors:  Osama N Kashlan; David V Laborde; Lakesha Davison; Amit M Saindane; Daniel Brat; Patricia A Hudgins; Robert E Gross
Journal:  Case Rep Neurol Med       Date:  2011-10-09

6.  Meningioangiomatosis without neurofibromatosis simulating encephalitis in neuroimaging.

Authors:  Everton Barbosa-Silva; Marcos Dellaretti; Gervásio Teles C de Carvalho; Júlio Leonardo Barbosa Pereira; Laelson Botrel; José Eymard H Pittella; Atos Alves de Sousa
Journal:  Surg Neurol Int       Date:  2012-03-19

7.  Meningioangiomatosis Without Neurofibromatosis Type 2.

Authors:  Sara Marzi; Danilo De Paulis; Alessandro Ricci; Graziano Taddei; Soheila Raysi Dehcordi; Gino Coletti; Giuliano Maselli; Renato J Galzio
Journal:  World J Oncol       Date:  2012-07-05

8.  Neuropathology of temporal lobe epilepsy.

Authors:  Fahd Al Sufiani; Lee Cyn Ang
Journal:  Epilepsy Res Treat       Date:  2012-04-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.